B

Bluewater Clinical Research Group | Sarnia, Canada

Research site
(Unclaimed)
Location
481 London Road, Sarnia, Ontario, Canada
Site insights

Top conditions

Type 2 Diabetes Mellitus (4 trials)

Migraine Disorders (4 trials)

Syndrome (3 trials)

Hypertriglyceridemia (3 trials)

Diabetes Mellitus (3 trials)

Top treatments

Olezarsen
ABP-450
Linaclotide
Empagliflozin
INV-202
Finerenone
Astegolimab
Piromelatine
Vibegron
Simufilam

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

16 of 24
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegaloviru...

Active, not recruiting
Cytomegalovirus
Biological: mRNA-1647
Other: Placebo

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Enrolling
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic...

Enrolling
Chronic Migraine
Biological: Botulinum toxin type A
Other: Placebo

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic...

Enrolling
Episodic Migraine
Biological: Botulinum toxin type A
Other: Placebo

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab
Drug: Placebo

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Empagliflozin Placebo

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine...

Invitation-only
Migraine
Drug: ABP-450

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per m...

Active, not recruiting
Migraine
Drug: ABP-450
Drug: Placebo

The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pedi...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Placebo (FC Participants)
Drug: Linaclotide 145 μg (IBS-C Participants)

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Invitation-only
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting
Alzheimer's Disease
Drug: Piromelatine 20 mg
Drug: Placebo

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting
Alzheimer Disease
Drug: Simufilam
Drug: Placebo

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the t...

Active, not recruiting
Obesity
Metabolic Syndrome
Drug: INV-202
Drug: Placebo

Trial sponsors

Ionis Pharmaceuticals logo

Ionis Pharmaceuticals (3 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems